Protocol Ledger

NCT06584032 · Phase III · RECRUITING

Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer

Interventional Phase III clinical trial protocol NCT06584032 sponsored by Hutchmed in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-12-12 Enrollment: 412 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06584032
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)412 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06584032
Protocol FieldVerified Registry Value
NCT IdentifierNCT06584032
Consolidated Lead SponsorHutchmed
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment412 participants (ESTIMATED)
Registered Start Date2024-12-12
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06584032
Hospital Research SiteLocationSite Profile
Chongqing Cancer HospitalChongqing, ChinaOpen Hospital Dossier ->
Fujian Cancer HospitalFuzhou, ChinaOpen Hospital Dossier ->
Sun Yat-sen University Cancer CenterGuangzhou, ChinaOpen Hospital Dossier ->
Guangxi Medical University Cancer HospitalNanning, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI